Soluble ST2 is associated with adverse outcome in patients with heart failure of ischaemic aetiology

In patients with ischaemic heart failure (HF), myocardial dysfunction often progresses. Elevated levels of soluble ST2 (sST2) are associated with a poor prognosis, but an association between sST2 and worsening heart failure per se has not been established. We assessed the association between sST2 and cause‐specific outcome in 1449 patients enrolled in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA study).

[1]  Pål Aukrust,et al.  Systemic inflammation in heart failure – The whys and wherefores , 2006, Heart Failure Reviews.

[2]  Ashley M. Miller,et al.  Serum soluble ST2: a potential novel mediator in left ventricular and infarct remodeling after acute myocardial infarction. , 2010, Journal of the American College of Cardiology.

[3]  J. McMurray,et al.  Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis , 2009, Circulation.

[4]  M. Picard,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2, Cardiac Structure and Function, and Long-Term Mortality in Patients With Acute Dyspnea , 2009, Circulation. Heart failure.

[5]  Juan Cinca,et al.  Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction. , 2009, Journal of the American College of Cardiology.

[6]  Michael J. Pencina,et al.  Statistical methods for assessment of added usefulness of new biomarkers , 2010, Clinical chemistry and laboratory medicine.

[7]  A. Boyle,et al.  The aging heart and post-infarction left ventricular remodeling. , 2011, Journal of the American College of Cardiology.

[8]  John G F Cleland,et al.  Predictors of fatal and non‐fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A‐1, high‐sensitivity C‐reactive peptide and N‐terminal pro B‐type natriuretic peptide , 2009, European journal of heart failure.

[9]  T. Mueller,et al.  Increased plasma concentrations of soluble ST2 are predictive for 1-year mortality in patients with acute destabilized heart failure. , 2008, Clinical chemistry.

[10]  S. Manzano-Fernández,et al.  Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. , 2011, The American journal of cardiology.

[11]  P. Young,et al.  Expression of ST2, an interleukin-1 receptor homologue, is induced by proinflammatory stimuli. , 1997, Biochemical and biophysical research communications.

[12]  G. Felker,et al.  Inflammatory biomarkers in heart failure. , 2006, Congestive heart failure.

[13]  Andreas Radbruch,et al.  T1/ST2 is preferentially expressed on murine Th2 cells, independent of interleukin 4, interleukin 5, and interleukin 10, and important for Th2 effector function. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[14]  J. McMurray,et al.  Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure). , 2009, Journal of the American College of Cardiology.

[15]  S. Réhman,et al.  Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. , 2008, Journal of the American College of Cardiology.

[16]  S. Manzano-Fernández,et al.  Soluble ST2, high‐sensitivity troponin T‐ and N‐terminal pro‐B‐type natriuretic peptide: complementary role for risk stratification in acutely decompensated heart failure , 2011, European journal of heart failure.

[17]  Richard T. Lee,et al.  IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. , 2007, The Journal of clinical investigation.

[18]  G. Fonarow,et al.  Epidemiology and risk stratification in acute heart failure. , 2008, American heart journal.

[19]  S. Redwood,et al.  Postinfarction left ventricular remodelling: where are the theories and trials leading us? , 2000, Heart.

[20]  T. Mueller,et al.  Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay. , 2009, Clinica chimica acta; international journal of clinical chemistry.

[21]  A. Bayés‐Genís,et al.  Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure. , 2010, Revista espanola de cardiologia.

[22]  D. Lloyd‐Jones,et al.  Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. , 2007, Journal of the American College of Cardiology.

[23]  Ewout W Steyerberg,et al.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers , 2011, Statistics in medicine.

[24]  Richard T. Lee,et al.  Serum Levels of the Interleukin-1 Receptor Family Member ST2 Predict Mortality and Clinical Outcome in Acute Myocardial Infarction , 2004, Circulation.

[25]  J Fernando Bazan,et al.  IL-33, an interleukin-1-like cytokine that signals via the IL-1 receptor-related protein ST2 and induces T helper type 2-associated cytokines. , 2005, Immunity.

[26]  Richard T. Lee,et al.  Complementary Roles for Biomarkers of Biomechanical Strain ST2 and N-Terminal Prohormone B-Type Natriuretic Peptide in Patients With ST-Elevation Myocardial Infarction , 2008, Circulation.

[27]  Richard T. Lee,et al.  Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker , 2003, Circulation.

[28]  R. Fitzgerald,et al.  Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure. , 2008, Journal of cardiac failure.

[29]  M. Clearfield.  Rosuvastatin in older patients with systolic heart failure. , 2009, Current atherosclerosis reports.

[30]  Richard T. Lee,et al.  The IL-33/ST2 pathway: therapeutic target and novel biomarker , 2008, Nature Reviews Drug Discovery.

[31]  M. V. Chávarri,et al.  La monitorización de ST2 soluble proporciona una estratificación del riesgo adicional en pacientes ambulatorios con insuficiencia cardiaca descompensada , 2010 .